AI
ENTA icon

Axiom Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

Axiom Investors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15,640
Closed -$619K – 162
2014
Q3 		$619K Buy
+15,640
New +$623K 0.02% 148

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Axiom Investors's ENTA Position: Q4 2014 in Review

Axiom Investors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2014, closing a stake of 15,640 shares — an estimated $619K sold.

Axiom Investors first reported a position in ENTA in Q3 2014 and held it in 1 quarter. The position peaked at $619K in Q3 2014. 124 funds tracked by Wall St. Rank hold ENTA as of Q4 2014.

  • Axiom Investors reported no remaining Enanta Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Axiom Investors sold 15,640 Enanta Pharmaceuticals shares in Q4 2014, an estimated $619K.
  • Axiom Investors first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Axiom Investors's Enanta Pharmaceuticals position peaked at $619K in Q3 2014.
  • 124 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2014.

Based on Axiom Investors's 13F filing for Q4 2014, filed 12 Feb 2015.